Net-a-Go Technology Company Limited
During the Interim Period, the Group recorded a total
revenue of approximately HK$105,424,000 (Corresponding
Period: approximately HK$102,657,000) representing
an increase of approximately 2.7% as compared to
the Corresponding Period. The increase was primarily
due to the increment of revenue from the cosmetic
products trading business and the development of media
advertisement business which overcome the drop of
revenue from the environmental maintenance business.
The cost of revenue is mainly comprised of service fees to
workers, material consumed, depreciation on machinery
and motor vehicles, motor vehicles expenses and utilities
expenses from the environmental maintenance business.
Cost of revenue for the Interim Period amounted to
approximately HK$97,843,000 (Corresponding Period:
HK$91,134,000), representing an increase of approximately
7.4% as compared to Corresponding Period.
The Group had 796 workers from the environmental
maintenance business in PRC and 102 office staff from
Hong Kong and PRC office, total 898 employees as at
30 June 2024 (As at 30 June 2023: 847 workers and 25
office staff, total 872 employees). The increase in office
staff mainly arising from the development of media
advertisement business. Salaries and benefits expenses for
workers were recognised as service fees to workers and
classified under cost of revenue while salaries and benefits
expenses for office staff were classified under general and
administrative expenses.
During the Interim Period, salaries and benefits expenses
were approximately HK$6,554,000 (Corresponding Period:
approximately HK$4,672,000). The Group would regularly
review the work allocation of the workers and office staff to
maintain a high standard of service.
Medical Devices Business
The Group starts to engage in the medical devices business after the completion of acquisition of medical devices business on 31 May 2022. The pen injector from the Company’s medical devices business is categorized as a Class II medical devices in China and has obtained the relevant certification approved by the National Medical Products Administration (“NMPA”).
The Company was granted with the International Organisation for Standardisation 13485
(“ISO 13485”) Certificate for meeting the regulatory requirements of the design, development and production of pen injector and has obtained the CE Full Quality Assurance System
Certificate (“CE marking”) for its pen injector for complying the product safety requirement
across Europe.
